Latest Lead News

Telix Pharmaceuticals has announced that Part 1 of its ProstACT Phase 3 trial for TLX591-Tx met its primary safety and dosimetry objectives, with no new safety concerns. The study’s success supports ongoing global enrolment in Part 2 and regulatory engagement in the US.

Miramar Resources has reported a standout shallow high-grade gold intersection at its Gidji JV Gold Project near Kalgoorlie, boosting hopes for a new gold resource. Further assays and drilling are underway to define the scale of this promising discovery.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

Westgold Resources has approved a $145 million expansion of its Higginsville Processing Hub, increasing capacity by 62.5% and aiming to lift Southern Goldfields production by 60,000 ounces annually while cutting processing costs by nearly a quarter.

Novo Resources Corp. has issued a prospectus offering free New Options to recent placement participants and joint lead managers, aiming to support its exploration projects in Western Australia and Victoria. The options, exercisable at A$0.15 and expiring in three years, could raise significant capital upon exercise, subject to shareholder approval.

Energy World Corporation appoints Alan Jowell as Executive Chairman to spearhead its strategic review and project development, while exploring asset sales alongside its flagship Pagbilao LNG and Power Project.

BluGlass has embarked on a A$1.25 million development program with a major US defence prime, receiving an initial A$560,000 order to develop cutting-edge visible GaN lasers for aerospace and defence applications.

Island Pharmaceuticals has partnered with the Burnet Institute to explore new antiviral applications for its lead drugs, targeting measles, chikungunya, and Ross River virus. This collaboration leverages existing data and government funding to enhance the company’s clinical pipeline without major capital outlay.

Pengana International Equities has dismissed an unauthorized announcement about management changes and outlined plans for a shareholder buy-back and potential special dividend amid its strategic review.

Dexus Convenience Retail REIT has extended its on-market securities buy-back program for another year, aiming to repurchase up to 2.5% of its securities to enhance shareholder value amid current trading conditions.

Rhythm Biosciences has achieved a significant regulatory milestone with NATA accreditation for its ColoSTAT® blood-based colorectal cancer test, enabling its commercial rollout in Australia and strengthening reimbursement prospects.

A new clinical study from Sichuan University confirms that TruScreen’s AI-enabled cervical cancer screening combined with high-risk HPV testing outperforms traditional cytology methods, reinforcing its global potential.